{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-041204","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2025-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.344644+00:00","generated_at":"2026-05-23T03:54:21.227966+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Entrada Therapeutics restructures, reduces workforce 20% to focus on Duchenne MD candidates","bullets":["Board approved strategic plan on April 29, 2025; workforce reduction of approximately 20% effective May 2.","Estimated $2 million in total charges (severance, healthcare) primarily in Q2 2025.","Company prioritizing DMD candidates ENTR-601-44, -45, -50, -51 and ocular programs.","Anticipates cost savings to extend cash runway into Q2 2027.","Workforce reduction substantially completed by end of Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-041204","json":"https://secwatch.observer/filing/0001104659-25-041204.json","markdown":"https://secwatch.observer/filing/0001104659-25-041204.md","text":"https://secwatch.observer/filing/0001104659-25-041204.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000110465925041204/0001104659-25-041204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000110465925041204/tm2513421d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T03:54:21.227966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"57fdcad6f6323fa3a442ad19e0db95dd2a99f5f4","claim":"Entrada Therapeutics, Inc. announced a restructuring with charges of approximately $2 million affecting research areas (approximately 20%).","evidence_excerpt":"-45, -50, and -51), ocular programs and maturing platform investments. In connection with the new strategic plan, the Company expects to incur aggregate charges of approximately $2 million in total expenses related to the reduction in force, consisting primarily of one-time severance payments and continued healthcare benefits for a specific period of time. The","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465925041204/0001104659-25-041204-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2 million"},{"label":"Affected area","value":"research areas"},{"label":"Headcount","value":"approximately 20%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}